Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hepion Pharmaceuticals Inc HEPA

Healthcare
Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of drug therapy for treatment of chronic liver diseases. The Company is developing a treatment for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), and other chronic liver diseases. Its cyclophilin inhibitor, rencofilstat, is being developed to offer benefits to address... see more

Recent & Breaking News (NDAQ:HEPA)

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger

GlobeNewswire November 11, 2024

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger

GlobeNewswire September 4, 2024

Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement

GlobeNewswire July 22, 2024

Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' Trial

GlobeNewswire April 19, 2024

Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell

GlobeNewswire March 6, 2024

Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds

GlobeNewswire February 16, 2024

Hepion Pharmaceuticals to Present at NASH-TAG 2024

GlobeNewswire January 3, 2024

Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes

GlobeNewswire December 7, 2023

Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit

GlobeNewswire November 28, 2023

Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease

GlobeNewswire November 13, 2023

Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 'ALTITUDE-NASH' Liver Function Trial of Rencofilstat

GlobeNewswire November 10, 2023

Hepion Pharmaceuticals' Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model

GlobeNewswire October 25, 2023

Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules

GlobeNewswire September 29, 2023

Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference

GlobeNewswire September 21, 2023

New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals' Rencofilstat in Cancer Screening Program

GlobeNewswire September 21, 2023

Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer

GlobeNewswire September 19, 2023

Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis

GlobeNewswire September 14, 2023

Hepion Pharmaceuticals Announces Management Changes

GlobeNewswire September 6, 2023

Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress(TM) 2023

GlobeNewswire June 15, 2023

Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b 'ASCEND-NASH' Trial of Rencofilstat

GlobeNewswire June 15, 2023